Jose Luis Luna

Responsible for the global commercial strategy of OFEV® (Nintedanib) across indications and stakeholder Launched OFEV® (Nintedanib) in SSc-ILD and PF-ILD worldwide Integrated and inspired a high-performing & highly motivated marketing team (seven direct reports / senior managers) Developed the strategic approach per customer and consolidated the brand positioning across the globe

Global marketing lead responsible for the launch preparation of OFEV® in SSc-ILD (Phase III). Design the commercial strategy for a successful launch and positioning of OFEV® in the field of rare diseases Challenge the status quo ensuring new practices take place to address key business questions. In some cases this is done by leveraging my experience in oncology into the field of rare diseases

Group lead responsible for all the commercial/marketing activities in the Oncology Business Unit in the the UK and Ireland. Responsible for the timely development and implementation of the marketing initiatives for the in-line compounds of the Business Unit Active collaboration with the BU Head Oncology to secure the profitability of the Unit within the corporation in the Region Ensure the marketing team is recognized as a top performer within the organization

- Global marketing leader for volasertib in acute myeloid leukemia/AML (Phase III) and myelodisplastic syndrome/MDS (Phase I/II) (breakthrough therapy designation in AML by the FDA in 2013). - Marketing responsible for the global launch of volasertib in AML and MDS including development of pre-launch and launch campaign, communication strategy, multichannel strategy and global internal training programme.

Strategic Analysis for decision making Responsible of the Head and Neck, Breast Cancer, AML indications in Phase II - III products Resposible for analysis and evaluation of Oncology Pipeline Products and their respective indications. Market Research implementation at Global Level.

- Successful development and implementation of the strategy & tactics to launch Afinitor (everolimus) for Renal Cell Carcinoma in México . - Development of local brand plan strategy and implementation tactics for three oncology compounds (Femara/Letrozole, Zometa/Zoledronic Acid and Afinitor/Everolimus) and their multiple indications - Multichannel strategy - Strategies focused on sales, people, customers and product.

- Initiator of the new market analysis and field force effectiveness function within the organization. - FF KPIs creation, implementation and evaluation. - Field Force Territory desigining. - Incentives calculation and control. - Market Research implementation. - Business Analysis for all brands in the franchise.

KPIs creation and evaluation for all the field force of the company. FF. Territory designing Field Force designing based on market size, cost, and potential. Field Force performance management.

Trends in Marketing. Business strategy and business plan. Corporate Strategy.

Marketing development. Administration. Business designing and implementation.